Bullish
Stifel maintained a Buy rating and $123.00 price target for Incyte (NASDAQ:INCY) after positive Phase 3 frontMIND data in diffuse large B-cell lymphom...
Bullish
Incyte (INCY) announced positive results from its Phase 3 frontMIND trial for tafasitamab combined with lenalidomide, showing a 25% reduction in disea...
Neutral
Incyte's Monjuvi, when used in a multi-drug regimen including chemotherapy for aggressive non-Hodgkin lymphoma, significantly reduced the risk of dise...
Incyte announced positive results from its Phase 3 frontMIND trial, showing that the combination of tafasitamab and lenalidomide with R-CHOP significa...
Neutral
Allstate Corp grew its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 105.7% in the 4th quarter, according to its most recent disclosur...
Neutral
Incyte (INCY) shares have fallen 1.8% since its last earnings report, underperforming the S&P 500. The company reported strong Q1 2026 adjusted earnin...
Incyte (Nasdaq: INCY) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:40 a.m. E...
Bullish
Incyte (NASDAQ: INCY) plans to initiate a Phase 3 trial for its mutant CALR antibody 989 in essential thrombocythemia (ET) around mid-year, following ...
Bullish
Incyte Corp. (NASDAQ: INCY) is highlighted as an investment opportunity due to a rare alignment of strong high growth momentum fundamentals and a prom...
Neutral
Bernstein has initiated coverage on Incyte (INCY) with a "Market Perform" rating and a price target of $99.00. GuruFocus indicates that INCY is slight...
Bullish
Incyte (INCY) has expanded its AI drug discovery partnership with Genesis Molecular AI, investing $120 million to leverage Genesis' GEMS platform for ...
Incyte (Nasdaq: INCY) has significantly expanded its collaboration with Genesis Molecular AI, investing $120 million to accelerate drug discovery usin...
Incyte (Nasdaq: INCY) has announced a strategic collaboration with Edison Scientific to integrate Edison's Kosmos AI platform into its drug discovery ...
Bullish
Northwestern Mutual Wealth Management Co. significantly increased its stake in Incyte Corporation (NASDAQ:INCY) by 5,218.5% in Q4, acquiring 585,618 a...
Bullish
The Ruxolitinib Market is projected for significant growth from 2026-2033, driven by strategic initiatives from major players like Incyte and Novartis...
Neutral
This article provides financial information for Incyte Corporation (ICY) on BX Swiss, specifically focusing on its free cash flow per share. The conte...